Search / 178 results found

from
to
  • Updated

BEVERLY, Mass. , Jan. 10, 2022 /PRNewswire/ -- Brookwood Financial Partners, LLC ("Brookwood"), a nationally-recognized private equity investment firm, announced today that it has sold 300 Jubilee Drive, a 163,067 square foot "best-in-class" industrial facility located in Peabody, MA.  Brookwood originally acquired the property for $8,000,000 on December 28, 2009 and sold the property for $43,155,000 to an affiliate of Lincoln Property Company.

  • Updated

NEWTON, Mass., Jan. 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Sohanya Cheng has been promoted to Chief Commercial Officer. She will be responsible for leading the Company's commercial strategy and operations, including the continued commercialization of XPOVIO® (selinexor). Ms. Cheng joined Karyopharm in 2021 as Senior Vice President of Sales and Commercial Operations. 

  • Updated

BURLINGTON, Mass., Jan. 6, 2022 /PRNewswire/ -- Nuance® Communications, Inc. (NASDAQ: NUAN) today announced it was named the market Leader in Opus Research's 2022 Intelligent Authentication and Fraud Prevention Report.1 Nuance Gatekeeper, a cloud–native biometric security solution that authenticates legitimate persons and detects fraudsters wherever and however they engage with brands, was recognized for its product completeness and flexibility, ranked highest among the 21 vendors evaluated in the report.

  • Updated

BEDFORD, Mass., Jan. 4, 2022 /PRNewswire/ -- Werfen today announced the 510(k) clearance of the GEM Hemochron 100 whole blood hemostasis system by the US Food and Drug Administration (FDA). Leveraging leading Hemochron technology, the GEM Hemochron 100 system, delivers fast, actionable activated clotting time (ACT) results in minutes, informing patient-management decisions and helping improve workflow at the point of care (POC). The GEM Hemochron 100 system is currently in clinical use in several European countries and will be commercialized in the US in early 2022.